{
  "id": "626aea6ae764a5320400003d",
  "type": "summary",
  "question": "What is Waylivra?",
  "ideal_answer": "Volanesorsen (Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31301033"
  ],
  "snippets": [
    {
      "text": "Volanesorsen (Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31301033",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}